Merck & Co., Inc. (MRK)
| Market Cap | 209.32B |
| Revenue (ttm) | 63.92B |
| Net Income (ttm) | 17.43B |
| Shares Out | 2.51B |
| EPS (ttm) | 6.88 |
| PE Ratio | 12.12 |
| Forward PE | 9.33 |
| Dividend | $3.24 (3.86%) |
| Ex-Dividend Date | Jun 16, 2025 |
| Volume | 9,717,076 |
| Open | 84.02 |
| Previous Close | 84.02 |
| Day's Range | 82.26 - 84.13 |
| 52-Week Range | 73.31 - 129.93 |
| Beta | 0.40 |
| Analysts | Buy |
| Price Target | 113.14 (+35.73%) |
| Earnings Date | Jul 29, 2025 |
About MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The company offers human health pharmaceutical for various areas, including oncology, vaccines, hospital acute care, cardiovascular, virology, neuroscience, and diabetes under the Keytruda, Welireg, Gardasil, ProQuad, M−M−R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janu... [Read more]
Financial Performance
In 2024, Merck & Co.'s revenue was $64.17 billion, an increase of 6.74% compared to the previous year's $60.12 billion. Earnings were $17.12 billion, an increase of 4589.59%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for MRK stock is "Buy." The 12-month stock price target is $113.14, which is an increase of 35.73% from the latest price.
News
Merck's Verona Acquisition: Plugging A $4B Hole In A $20B Gap
Merck's recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent cliff. The pharmaceutical leader has made an agreement to acquire the COPD d...
FDA Approves BRAVECTO® QUANTUM (Fluralaner for Extended-Release Injectable Suspension) from Merck Animal Health
RAHWAY, N.J.--(BUSINESS WIRE)--Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced t...
U.S. FDA Accepts New Drug Application for Merck's Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--U.S. FDA Accepts New Drug Application for Merck's DOR/ISL Once-Daily Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1.
Measuring Options Activity in MRK & XLV: Healthcare Levels to Watch
Rick Ducat turns to the healthcare sector on today's options analysis. He starts with the SPDR Health Care ETF (XLV), noting the recent breakdown of a head and shoulders pattern and potential for both...
Major deals involving U.S. drugmakers and biotechs over the past decade
Merck is acquiring UK-based Verona Pharma for about $10 billion, as part of the U.S. drugmaker's strategy to diversify beyond its blockbuster cancer treatment Keytruda.
Undercovered Dozen: Roku, Merck, Chevron And More
The Undercovered Dozen series highlights 12 lesser-covered stocks weekly, providing investment ideas and sparking community discussion on their potential. Roku, Serve Robotics, Merck, Aeva, Chevron, I...
Merck to Buy Verona Pharma for Around $10 Billion
Merck agreed to buy respiratory drugmaker Verona Pharma for about $10 billion as it tries to make up for huge expected patent losses. Sales could fall by $18 billion over the next five years.
Merck has struck a roughly $10 billion deal to buy Verona Pharma
The move bolsters Merck's lineup as it braces for the 2028 loss of patent exclusivity for blockbuster cancer drug Keytruda.
META Stake in Ray-Ban & Oakley Maker, MRK Acquiring VRNA, TMUS Downgrade
Meta Platforms (META) is moving to eyewear. As Diane King Hall explains, the Mag 7 giant is seeking to build its own A.I.
Merck to buy Verona for $10 billion ahead of Keytruda patent expiration
CNBC's Angelica Peebles reports on themes emerging in the pharma space.
Merck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
Merck & Co. Inc. MRK agreed on Wednesday to acquire Verona Pharma plc VRNA for $107 per American Depository Share (ADS) for a total transaction value of approximately $10 billion. Each ADS represents ...
Merck dives into COPD treatments with $10 billion purchase of Verona Pharma
Verona Pharma's stock soars toward a record after $10 billion buyout deal with Merck.
Merck buys Verona for $10 billion
Evan Seigerman, BMO senior biopharma analyst, joins 'Squawk Box' to discuss Merck's decision to buy Verona, the potential impact of sector tariffs and much more.
Verona Pharma Stock Jumps 21%. It's Being Bought for $10 Billion by Merck.
The deal is expected to close in the fourth quarter of 2025.
Merck to Buy Verona Pharma in $10 Billion Deal
Merck has struck a roughly $10 billion deal to buy Verona Pharma, bolstering its lineup as it braces for the 2028 loss of patent exclusivity for the blockbuster cancer drug Keytruda.
Merck to acquire Verona Pharma for $10 billion
Merck will buy UK-based Verona Pharma for about $10 billion, the companies said on Wednesday, strengthening the U.S. firm's presence in respiratory treatments as it readies for the patent expiry of it...
Merck to Acquire Verona Pharma, Expanding its Portfolio to Include Ohtuvayre® (ensifentrine), a First-In-Class COPD Maintenance Treatment for Adults and Expected to Drive Growth into the Next Decade
RAHWAY, N.J. & RALEIGH, N.C.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical comp...
Merck nears $10 billion deal for respiratory drugmaker Verona, FT reports
Merck is nearing a roughly $10 billion deal to buy lung disease-focused biotech Verona Pharma, the Financial Times reported on Wednesday.
Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025
RAHWAY, N.J.--(BUSINESS WIRE)---- $MRK #MRK--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that new data from its research pipeline for HIV prevention and tr...
My Top 10 High-Yield Dividend Stocks For July 2025: One Yields 12%-Plus
I present my top 10 high-yield dividend stocks for July 2025, screened for strong yields, large market caps, and attractive valuations. The list includes Chevron, Pfizer, PepsiCo, Ares Capital, BB Seg...
Merck & Co.: A Pharma Titan At A Discount
Merck & Co. (MRK) is currently down ≈18% YTD, a result of the 2028 patent cliff, weak demand for Gardasil in China, and IRA price controls. Despite these headwinds, my DCF Model shows that at its curr...
5 Relatively Secure And Cheap Dividend Stocks, Yields Up To 9% (July 2025)
This article is part of our monthly series where we highlight five large-cap, relatively safe, dividend-paying companies offering significant discounts to their historical norms. We go over our filter...
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
FDA Grants Priority Review for WINREVAIR™ (sotatercept-csrk) to Update Label Based on Results From ZENITH Trial
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted priori...
Top 15 High-Growth Dividend Stocks For July 2025
My Top 15 High-Growth Dividend Stocks outperformed SPY and VIG in June, gaining 6.15% versus SPY's 5.14% and VIG's 3.41%. The list's year-to-date return is 12.59%, beating SPY every month in 2025, tho...